In a significant revelation, internal records have surfaced indicating that high-ranking officials from the Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, in June 2025 to discuss ongoing litigation regarding glyphosate, the active ingredient in the company’s widely used herbicide, Roundup. This meeting occurred mere months before the Trump administration took deliberate actions to bolster Bayer’s legal position in the face of mounting cancer-related lawsuits.
High-Stakes Discussion
The meeting, held on 17 June 2025, involved key figures from the EPA, including Lee Zeldin, the agency’s administrator, as well as Nancy Beck, Sean Donahue, and Turner Bridgforth. Their discussions reportedly centered around “litigation issues” and potential “supreme court action” concerning glyphosate, a matter of increasing public concern given the numerous lawsuits alleging that the chemical contributes to cancer development.
Bayer is currently embroiled in litigation brought forth by tens of thousands of individuals who claim to have developed cancer as a result of using glyphosate-based products. The company’s strategy hinges on persuading the Supreme Court to accept its argument that if the EPA does not mandate a cancer warning for glyphosate products, Bayer cannot be held liable for any alleged health risks. This position has seen mixed success in the courts, with some rulings favouring Bayer while others have rejected its arguments.
Regulatory Support for Bayer
Since the June meeting, the Trump administration’s backing of Bayer has become increasingly apparent. Notably, in a 1 December 2025 filing, Solicitor General D. John Sauer urged the Supreme Court to hear Bayer’s case, a request that was subsequently granted, scheduling a hearing for 27 April 2026. Additionally, in February 2026, the White House invoked the Defense Production Act to safeguard glyphosate production, providing further support to Bayer and its affiliates.
Bayer has maintained that their meeting with EPA officials was a routine aspect of the regulatory process and insists that they have been transparent regarding their legal challenges. However, the timing and nature of the discussions have raised eyebrows among environmental advocates and legal experts alike.
Concerns About Corporate Influence
The implications of such a high-profile meeting have sparked considerable debate. Nathan Donley, director of environmental health science at the Centre for Biological Diversity, expressed alarm over the apparent prioritisation of corporate interests over public health. He remarked, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.”
Legal experts have also voiced concerns regarding the accessibility of regulatory discussions. Whitney Di Bona, a consumer safety advocate, questioned whether individuals affected by glyphosate had been afforded similar opportunities to speak with the EPA, highlighting a troubling disparity in how corporate entities interact with regulatory bodies compared to ordinary citizens.
A Pattern of Access and Influence
Naomi Oreskes, a professor at Harvard University, pointed out that the meeting exemplifies a broader trend where industry leaders enjoy an advantageous relationship with government officials, overshadowing the voices of the public. Meanwhile, advocates like Zen Honeycutt, founder of Moms Across America, have echoed these sentiments, noting that while their organisation has sought dialogue with the EPA, meaningful change remains elusive.
Why it Matters
This unfolding story underscores a critical intersection of corporate power and public health, raising urgent questions about the integrity of regulatory processes. As legal battles over glyphosate continue, the potential influence of corporate interests on health regulations poses a significant threat to consumer safety. The outcome of these legal proceedings and the subsequent regulatory actions will not only impact Bayer’s future but also set a precedent for how corporate entities interact with public health policies. The stakes could not be higher, as they intertwine with the health and well-being of countless individuals across the nation.
